Interaction of eight steroid derivatives with VEGFR-1 using a theoretical model
-
Published:2024-02-23
Issue:3
Volume:3
Page:11-24
-
ISSN:2764-3417
-
Container-title:Brazilian Journal of Science
-
language:
-
Short-container-title:Braz. J. of Sci.
Author:
Lopez-Ramos MariaORCID, Figueroa-Valverde LauroORCID, Alvarez-Ramirez MagdalenaORCID, Rosas-Nexicapa MarcelaORCID, Mateu-Armand Maria VirginiaORCID, Cauich-Carrillo ReginaORCID
Abstract
Some vascular endothelial growth factor receptor-1 (VEGFR-1) inhibitors drugs have been used to cancer cells; however, their interaction with VEGFR-1 is very confusing. The objective of this research was to evaluate the possible interaction of eight steroid derivatives with VEGFR-1 surface using 3hgn protein, cabozantinib, pazopanib, regorafenib, and sorafenib as theoretical tools in DockingServer program. The results showed some differences in the interaction of the steroid derivatives (1-8) with the 3hng protein surface such as i) differences in the number of amino acids; ii) different position of some amino acids compared to cabozantinib, pazopanib, regorafenib, and sorafenib. Besides, the inhibition constant (Ki) for steroid derivatives 1, 3, 6 and 8 was lower compared to cabozantinib and sorafenib drugs. In addition, other data display that Ki for steroid analogs 1, 3, 4, 6, 7 and 8 was lower compared with pazopanib and regorafenib. In conclusion, all these data suggest that steroid derivatives 1, 3, 4, 6, 7 and 8 could act as VEGFR-1 inhibitors and this phenomenon could be translated as good compounds to treat cancer cells.
Publisher
Lepidus Tecnologia
Reference64 articles.
1. Atzori, M., Ceci, C., Ruffini, F., Trapani, M., Barbaccia, M., Tentori, L., D’Atri, S., Lacal, P. M., Graziani, G. (2020). Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib. Journal of Cellular and Molelcular Medicine, 24(1): 465-475. https://doi.org/10.1111/jcmm.14755 2. Banerjee, P., Eckert, A., Schrey, A., & Preissner, R. (2018). ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Research, 46(W1), W257-W263. https://doi.org/10.1093/nar/gky318 3. Banerjee, S., Velásquez-Zapata, V., Fuerst, G., Elmore, J., & Wise, R. (2021). NGPINT: a next-generation protein–protein interaction software. Briefings in Bioinformatics, 22(4), 1-14. https://doi.org/10.1093/bib/bbaa351 4. Bekaii-Saab, T., Ou, F., Ahn, D., Boland, P., Ciombor, K., & Heying, E. (2019). Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. The Lancet Oncology, 20(8), 1070-1082. https://doi.org/10.1016/S1470-2045(19)30272-4 5. Bianco, R., Rosa, R., Damiano, V., Daniele, G., Gelardi, T., & Garofalo, S. (2008). Vascular endothelial growth factor
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|